Most Read Articles
Roshini Claire Anthony, 20 Oct 2020

The increased risk of mortality among patients with cancer diagnosed with COVID-19 may be due to their older age and presence of comorbidities, according to a study presented at ECCVID 2020.

Pank Jit Sin, 02 Nov 2020
Application for Sputnik V, the tradename of the world’s first registered COVID-19 vaccine, has been submitted to the WHO for accelerated registration via the Emergency Use Listing (EUL) and prequalification. 

Rhinovirus, IFV A/B prevalent in asthmatics with acute exacerbations

Stephen Padilla
04 Dec 2017

About one in five (~20 percent) of lower respiratory tract illnesses (LRTIs) involve respiratory viruses irrespective of the presence of asthma exacerbation, according to a Korea study presented at the 22nd Congress of the Asian Pacific Society of Respirology (APSR) held in Sydney, Australia.

The most common viruses are rhinovirus (RV), influenza virus (IFV) A and IFV B. In addition, there are some patients who experienced frequent viral infections followed by asthma exacerbations.

“Viral infections are involved in approximately 50 percent of exacerbations among Caucasian adult asthmatics. However, there have been few reports on the causative virus exacerbations in Korean adult asthmatics,” the authors said.

Frequencies and types of viruses between LRTIs with (exacerbated) and without (stable) exacerbations were compared to determine the contribution of respiratory viruses to exacerbations.

The authors used the Viral Gene-spin Kit to extract viral RNA from sputum. They also performed reverse transcription-polymerase chain reaction (RT-PCR) to detect adenovirus (ADV), metapneumovirus (MPV), parainfluenza virus (PIV) 1/2/3, IFV A, IFV B, respiratory syncytial virus (RSV) A/B and RV A.

A total of 259 patients were included, of which 210 underwent a single sputum examination and 49 underwent two to four sputum examinations. Respiratory viruses were identified in 68 of the 259 exacerbated episodes and in 11 of the 64 stable episodes. [APSR 2017, abstract AP189]

The most frequently detected virus among the exacerbated episodes was RV, followed by IFV A, PIV, RSV A/B and ADV. RV was also the most common virus among the 11 stable episodes. The two groups did not differ in the detection rates of these viruses (p>0.05). [Allergy Asthma Immunol Res 2017;9:491-498]

Thirty-five patients underwent virus examination at two episodes of exacerbation, while 14 patients underwent at each time of exacerbated and stable episodes. There was significantly higher virus detection rate at the second examination in cases with two exacerbation episodes than in those with initial exacerbation and sequential stable episodes (p=0.003).

The authors also noted a seasonal pattern in the detection rates of RV (September to December), IFV (January to April), PIV (May to September) and RSV A/B (September to April).

In another study involving Korean children with LRTIs, researchers found that RV and IFV correlated with hospitalization for asthma exacerbation in children with atopic sensitization. Compared to other LRTIs, RV or IFV was more frequent in asthma exacerbations. [Korean J Pediatr 2014;57:29-34]

These findings also support the results of a previous systematic review of studies involving patients with exacerbations of chronic obstructive pulmonary disease (AECOPD). Researchers found that rhino-/enteroviruses, RSV and IFVs were more prevalent in both upper and lower respiratory tract samples in patients with AECOPD. [J Clin Virol 2014;61:181-8]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 20 Oct 2020

The increased risk of mortality among patients with cancer diagnosed with COVID-19 may be due to their older age and presence of comorbidities, according to a study presented at ECCVID 2020.

Pank Jit Sin, 02 Nov 2020
Application for Sputnik V, the tradename of the world’s first registered COVID-19 vaccine, has been submitted to the WHO for accelerated registration via the Emergency Use Listing (EUL) and prequalification.